Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

BJU international·2026

Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Same author

Improved prostate cancer grading by incorporating Gleason pattern quantification, invasive cribriform and intraductal carcinoma in the new QUICC-score.

Annals of diagnostic pathology·2026

Same author

[Screening for prostate cancer; a screening program is favored over current opportunistic testing].

Nederlands tijdschrift voor geneeskunde·2026

Same author

From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?: Editorial to: Nguyen DD, Tadayon B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. 2026. In press. https://doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026

Same author

Use of Artificial Intelligence in prostate MRI: A rapid scoping review highlighting limited evidence in screening context.

European journal of radiology·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

The prostate-specific antigen test.

Monique J Roobol¹

¹Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands. m.roobol@erasmusmc.nl

Expert Opinion on Medical Diagnostics

|July 24, 2013

Summary

Prostate cancer (PC) screening with prostate-specific antigen (PSA) tests reduces mortality but causes overdiagnosis. The focus should be on informed, balanced use of PSA testing, not abandonment or unrestricted access.

Area of Science:

Urology
Oncology
Public Health

Background:

Prostate cancer (PC) was historically a high-mortality disease, with a 1 in 2-3 mortality-incidence ratio before the 1980s.
Autopsy studies revealed high prevalence of latent PC in middle-aged men, suggesting a disconnect between disease presence and clinical significance.
The FDA approved prostate-specific antigen (PSA) in 1986 for treatment monitoring and in 1994 for PC screening aid.

Discussion:

Systematic PSA-based screening demonstrably reduces metastatic disease and PC mortality compared to minimal screening.
However, widespread PSA screening is associated with significant overdiagnosis and unnecessary testing.
The debate centers on abandoning PSA testing versus unrestricted availability, with a middle ground proposed.

Key Insights:

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 9, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

PSA screening effectively lowers prostate cancer mortality and suffering from metastatic disease.
Overdiagnosis and overtreatment are significant concerns linked to current PSA screening practices.
A balanced approach is needed, emphasizing informed patient decision-making.

Outlook:

Future strategies should focus on optimizing PSA testing protocols to maximize benefits while minimizing harms.
Enhanced patient education regarding the risks and benefits of PSA testing is crucial.
Continued research is needed to refine PC screening guidelines and diagnostic criteria.